Abstracts tagged "Lupus"

Abstract Number: 1680 • 2018 ACR/ARHP Annual Meeting
Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?
Jordi Camins Fàbregas¹, Melania Martinez-Morillo¹, Laia Gifre¹, Susana Holgado¹, Lourdes Mateo², Maria Aparicio¹, Anne Riveros², Ivette Casafont-Solé¹, Yaiza Garcia¹, Agueda Prior³, Aina Teniente-Serra⁴, Eva Martínez-Cáceres⁴ and Alejandro Olivé-Marqués², ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴Immunology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Clinical manifestations of systemic lupus erythematosus (SLE) and infections sometimes are difficult to distinguish. In clinical practice low complement and anti(ds)DNA levels are used…
Abstract Number: 2099 • 2018 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Inhibition Modulates Multiple Cell Types Instrumental in the Pathogenesis of Lupus Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Elliott Klein², Jay S. Fine², Gerald Nabozny³, Meera Ramanujam² and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ³[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE) that adds substantial morbidity and mortality. Passive transfer of pre-formed nephritogenic antibodies…
Abstract Number: 2684 • 2018 ACR/ARHP Annual Meeting
Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients
Katie Streicher¹, Jixin Wang¹, Philip Z. Brohawn², Brandon W. Higgs², Raj Tummala³ and Koustubh Ranade⁴, ¹Translational Medicine, MedImmune, Gaithersburg, MD, ²MedImmune LLC, Gaithersburg, MD, ³MedImmune, Gaithersburg, MD, ⁴Translational Medicine, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Type I interferon has been identified as one of the central mediators in the pathogenesis of SLE, such that patients are characterized by activation…
Abstract Number: 395 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis
Nicole Bitencourt, Elizabeth (Blair) Solow and Bonnie L. Bermas, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The goal of this study was to identify specific clinical features of patients with SLE who have inflammatory myositis. Methods: A retrospective chart review…
Abstract Number: 743 • 2018 ACR/ARHP Annual Meeting
Outcome of Stroke in Patients with Systemic Lupus Erythematosus: A Nested Case-Control Study
Chi Chiu Mok, Lap Kiu Tsoi and Yat Pang Fu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To evaluate the outcome of stroke in patients with systemic lupus erythematosus (SLE) in comparison with non-SLE patients. Methods: Patients who fulfilled ≥4 SLICC/ACR…
Abstract Number: 1689 • 2018 ACR/ARHP Annual Meeting
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus
Nathaniel J. Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Department of Medicine, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus Background/Purpose: Patient-reported measures of disease activity provide useful adjuncts to…
Abstract Number: 2100 • 2018 ACR/ARHP Annual Meeting
Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus
Samantha Chalmers¹, Sayra Garcia¹, Andrew Draganski¹, Jessica Doerner², Adam Friedman³, Joel Friedman¹ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Pennsylvania, Philadelphia, PA, ³Dermatology, GW School of Medicine and Health Sciences, Washington, DC, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Cutaneous lupus erythematosus (CLE) affects ~75% of SLE patients and has a profound impact on quality of life. While the morbidity from CLE is…
Abstract Number: 2796 • 2018 ACR/ARHP Annual Meeting
Sex-Based Differences Control ABC Function in Swef-Deficient Mice
Michela Manni¹, Danny Flores-Castro², Chao Ye², Edd Ricker¹, Sanjay Gupta³, Yurii Chinenov⁴, Tania Pannellini² and Alessandra B. Pernis⁵, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ⁴Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁵David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Age-associated B cells (ABCs) are a novel B cell subset, which expands with age in non-autoimmune mice but accumulates prematurely in autoimmune-prone strains. ABCs…
Abstract Number: 459 • 2018 ACR/ARHP Annual Meeting
Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
Angel Alberto Herrera Guerra¹, Sampath Prahalad¹, Kelly A. Rouster-Stevens¹, Rouba Garro², Leah Bryan³ and Yin Hong⁴, ¹Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Pediatric Nephrology, Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pathology, Children's Health Care of Atlanta, Atlanta, GA
Background/Purpose: There is a paucity of data regarding the early hospital readmission rates in newly diagnosed childhood lupus nephritis (cLN). We conducted a retrospective study…
Abstract Number: 748 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival of Renal Transplantation Due to Lupus Nephritis. Comparative Study with Non-Autoimmune Transplantation. Study from a Single Center
Lara Sánchez-Bilbao¹, Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Marina de Cos-Gómez², Íñigo González-Mazón¹, Diana Prieto Peña³, Monica Calderón Goercke³, Juan Carlos Ruiz San Millán², Emilio Rodrigo Calabia², Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus, affecting up to 40% of patients. Unfortunately, about 20% of LN develop end…
Abstract Number: 1707 • 2018 ACR/ARHP Annual Meeting
Prolactin and Dehydroepiandrosterone Sulfate in Women with Active Systemic Lupus Erythematosus of Recent Onset Versus Chronic Inactive Patients
Olga Vera-Lastra¹, Cristopher Vázquez², María Pilar Cruz-Dominguez³ and Luis J. Jara-Quezada⁴, ¹Internal Medicine, Hospital de Especialidades Centro Medico nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ²Internal medicine Department, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ³Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional "La Raza", Mexico City, Mexico, ⁴Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional,, Mexico, Mexico
Background/Purpose: Prolactin has a role in pathogenesis of Systemic Lupus Erythematous (SLE); high levels have been associated with activity. In contrast, a decrease in dehydroepiandrosterone…
Abstract Number: 2114 • 2018 ACR/ARHP Annual Meeting
Interferon Kappa Regulates Apoptotic Response to UVB in Control and Lupus Keratinocytes
Grace Hile¹, Mrinal Sarkar², Jianhua Liu³, Tamra J. Reed⁴, Johann Gudjonsson² and Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²Dermatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Photosensitivity, defined as increased cutaneous erythema and inflammation after ultraviolet light (UV) exposure, is a hallmark of patients with systemic lupus erythematosus (SLE), cutaneous…
Abstract Number: 2807 • 2018 ACR/ARHP Annual Meeting
Association of Exposure to Childhood Abuse with Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women
Candace H. Feldman¹, Susan Malspeis², Cianna Leatherwood¹, Laura Kubzansky³, Karen Costenbader¹ and Andrea Roberts⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Prior studies demonstrated associations between post-traumatic stress disorder and increased risk of incident SLE and between childhood trauma and increased risk of hospitalization for…
Abstract Number: 461 • 2018 ACR/ARHP Annual Meeting
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
Anna Carmela Sagcal-Gironella¹, Eyal Muscal², Andrea A. Ramirez¹, Monica Marcus³, Miriah Gillispie¹, William Blaine Lapin¹ and Marietta M. De Guzman⁴, ¹Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, ³Deaprtment of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Ofatumumab is a fully human anti-CD20 monoclonal antibody that has been approved for the treatment of chronic lymphocytic leukemia. It has been increasingly used…
Abstract Number: 750 • 2018 ACR/ARHP Annual Meeting
Positive Remodeling Index and Low Attenuation Non-Calcified Coronary Plaques: Markers of Vulnerable Coronary Plaques in Systemic Lupus?
George Stojan¹, Laurence Magder² and Michelle Petri³, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Department of Epidemiology, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. Positive remodeling index and presence of low…

« Previous Page
1
…
7
8
9
10
11
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].